Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.

NCT00640159 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00640159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00640159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.
Lead sponsor
Baylor College of Medicine
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
August 31, 2008
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease